Skip to main content
. 2016 Jan 7;8(1):11. doi: 10.3390/cancers8010011

Figure 2.

Figure 2

Antitumor activity of OXi4503 in the subcutaneous FaDu-luc xenograft model of human head and neck squamous cell carcinoma (HNSCC). Temporal tumor volume curves of control and OXi4503 treated mice calculated from caliper measurements. A single dose of OXi4503 (40 mg/kg, i.p.) led to a significant inhibition of tumor growth compared to untreated controls. (n = 4–6 per group). Values represent mean ± standard deviation at each time point. * denotes p < 0.05, ** denotes p < 0.001, *** denotes p < 0.0001.